FDA Okays First DDP-4 Inhibitor for Type 2 Diabetes

News
Article

ROCKVILLE, Md. -- The FDA approved Januvia (sitagliptin) today, the first dipetidyl peptidase-4 (DDP-4) inhibitor, an oral agent for type 2 diabetes as monotherapy or in combination with Glucophage (metformin) or a PPAR agonist.

ROCKVILLE, Md., Oct. 17 -- The FDA approved Januvia (sitagliptin) today, the first dipetidyl peptidase-4 (DDP-4) inhibitor, an oral agent for type 2 diabetes.

The agent was approved as monotherapy or in combination with Glucophage (metformin) or a peroxisome proliferator-activated receptor (PPAR) agonist, such as Actos (pioglitazone).or Avandia (rosiglitazone).

The price of once-daily Januvia, marketed by Merck, was not disclosed by press reports put it in the range of a pill. Another DDP-4 called Glavus, made by Novartis, is awaiting FDA approval.

Januvia was evaluated in a total of 2,719 patients with type 2 diabetes, in studies lasting from 12 weeks to more than a year, according to the FDA. These studies demonstrated improved blood sugar control when Januvia was used alone or in patients not satisfactorily managed with metformin or a PPAR agonist.

The most common side effects in clinical studies were upper respiratory tract infection, sore throat, and diarrhea.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
© 2025 MJH Life Sciences

All rights reserved.